References
2. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med 2004. 454S–14S.
3. Tian M, Zhang H, Nakasone Y, Mogi K, Endo K. Expression of Glut-1 and Glut-3 in untreated oral squamous cell carcinoma compared with FDG accumulation in a PET study. Eur J Nucl Med Mol I 2004. 315–12.
4. Tohma T, Okazumi S, Makino H, Cho A, Mochiduki R, Ochiai T, et al. Relationship between glucose transporter, hexokinase and FDG-PET in esophageal cancer. Hepato-Gastroentero 2005. 52486–490.
5. Nakamoto Y, Osman M, Cohade C, Marshall LT, Links JM, Wahl RL, et al. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images. J Nucl Med 2002. 431137–1143.
6. Beyer T, Antoch G, Muller S, Egelhof T, Freudenberg LS, Bockisch A, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004. 4525S–35S.
7. Vogel WV, Oyen WJ, Barentsz JO, Kaanders JH, Corstens FH. PET/CT: panacea, redundancy, or something in between? J Nucl Med 2004. 4515S–24S.
8. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001. 421S–93S.
10. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Cox JD, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005. 231136–1143.
11. Choi JY, Jang HJ, Shim YM, Kim K, Lee KS, Kim BT, et al. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 2004. 451843–1850.
13. Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Israel O, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003. 441200–1209.
14. Schoder H, Yeung HW, Gonen M, Kraus D, Larson SM. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 2004. 23165–72.
15. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Steinert HC, et al. Staging of non-small-cell lung cancer with integrated positron emission tomography and computed tomography. New Engl J Med 2003. 3482500–2507.
16. Menda Y, Graham MM. Update on 18F-fluorodeoxy-glucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Semin Nucl Med 2005. 35214–219.
17. Yuan S, Yu Y, Chao KS, Fu Z, Yin Y, Yu J, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 2006. 471255–1259.
18. Choi JY, Lee KS, Kwon OJ, Shim YM, Baek CH, Kim BT, et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 2005. 237654–7659.
19. van Der Wel A, Nijsten S, Hochstenbag M, Lamers R, Boersma L, De Ruysscher D, et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol 2005. 61649–655.
20. Brianzoni E, Rossi G, Ancidei S, Berbellini A, Capoccetti F, Algranati C, et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 2005. 321392–1399.